Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy

被引:2
|
作者
Chen, Wei-Chun [1 ,2 ,3 ,4 ,5 ]
Chang, Ting-Chang [1 ]
Chou, Hung-Hsueh [1 ,6 ]
Cheng, Mei-Hsiu [7 ]
Hong, Jun-Jie [7 ]
Hsieh, Yi-Shan [7 ]
Cheng, Chao-Min [4 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Dept Obstet & Gynecol,Div Gynecol Oncol, Coll Med, Taoyuan 333, Taiwan
[2] New Taipei City Municipal Tucheng Hosp, Dept Obstet & Gynecol, New Taipei 236, Taiwan
[3] Natl Tsing Hua Univ, Int Intercollegiate PhD Program & Inst Biomed Engn, Hsinchu 300, Taiwan
[4] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 300, Taiwan
[5] Chang Gung Univ, Sch Tradit Chinese Med, Taoyuan 333, Taiwan
[6] Natl Tsing Hua Univ, Sch Med, Hsinchu 300, Taiwan
[7] Inti Taiwan Inc, Taiwan Business Dev Dept, Hsinchu 302, Taiwan
关键词
ovarian cancer; cytoreduction surgery; hyperthermic intraperitoneal chemotherapy; HIPEC; miRNA; cytokine; ENDOTHELIAL GROWTH-FACTOR; REGULATORY T-CELLS; MALIGNANT ASCITES; GASTRIC-CANCER; CLINICAL-SIGNIFICANCE; LUNG ADENOCARCINOMA; PROMOTES INVASION; EXPRESSION; PROGRESSION; DISEASE;
D O I
10.3390/ijms24119748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study investigated miRNA and cytokine expression changes in peritoneal fluid samples of patients with advanced ovarian cancer (OVCA) after receiving hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreduction surgery (CRS). We collected samples prior to HIPEC, immediately after HIPEC, and 24/48/72 h after CRS from a total of 6 patients. Cytokine levels were assessed using a multiplex cytokine array, and a miRNA PanelChip Analysis System was used for miRNA detection. Following HIPEC, miR-320a-3p, and miR-663-a were found to be immediately down-regulated but increased after 24 h. Further, significant upregulation post-HIPEC and sustained increases in expression were detected in six other miRNAs, including miR-1290, miR-1972, miR-1254, miR-483-5p, miR-574-3p, and miR-574-5p. We also found significantly increased expression of cytokines, including MCP-1, IL-6, IL-6sR, TIMP-1, RANTES, and G-CSF. The changing expression pattern throughout the study duration included a negative correlation in miR-320a-3p and miR-663-a to cytokines including RANTES, TIMP-1, and IL-6 but a positive correlation in miRNAs to cytokines including MCP-1, IL-6sR, and G-CSF. Our study found miRNAs and cytokines in the peritoneal fluid of OVCA patients demonstrated different expression characteristics following CRS and HIPEC. Both changes in expression demonstrated correlations, but the role of HIPEC remains unknown, prompting the need for research in the future.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Debate on hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer
    Van Driel, Willemin
    Vergote, Ignace
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (04) : 454 - 455
  • [32] Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer
    Wang, Joyce Y.
    Gross, Maya
    Urban, Renata R.
    Jorge, Soledad
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, : 313 - 329
  • [33] Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer
    Hager, ED
    Dziambor, H
    Höhmann, D
    Mühe, N
    Strama, H
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 : 57 - 63
  • [34] Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis
    Loggie, BW
    Fleming, RA
    Geisinger, KR
    ACTA CYTOLOGICA, 1996, 40 (06) : 1154 - 1158
  • [35] Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis
    McQuellon, RP
    Loggie, BW
    Fleming, RA
    Russell, GB
    Lehman, AB
    Rambo, TD
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (01): : 65 - 73
  • [36] Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy
    Lopez-Rojo, Irene
    Olmedillas-Lopez, Susana
    Villarejo Campos, Pedro
    Dominguez Prieto, Victor
    Barambio Buendia, Javier
    Cortes Guiral, Delia
    Garcia-Arranz, Mariano
    Garcia-Olmo, Damian
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [37] Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinosis
    Hildebrandt, B
    Rau, B
    Gellermann, J
    Wust, P
    Riess, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1527 - 1529
  • [38] Peritoneal metastasis of advanced epithelial ovarian carcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective international multicentric data analysis
    Torun, Bahar Canbay
    Glehen, Olivier
    Kepenekian, Vahan
    Sardi, Armando
    Arjona-Sanchez, Alvaro
    Yonemura, Yutaka
    Barat, Shoma
    Morris, David
    Spiliotis, John
    Coccolini, Federico
    Sommariva, Antonio
    Bartos, Adrian
    Raza, Sayyed
    Vander Speteen, Kurt
    Akin, Levhi
    Irez, Tulay
    Canbay, Emel
    EJSO, 2023, 49 (08): : 1489 - 1494
  • [39] Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen, K. M.
    Rodriguez, N.
    Horowitz, N. S.
    Campos, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis
    Tang, Qin
    Huang, Mao
    Zhang, Jing
    Huang, Zhen
    Wang, Linlian
    Gong, Zhengxin
    Tang, Liangdan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)